Nanostics

Apr 23, 2025

Nanostics Launches Clinical Utility Study for Its AI-Powered ClarityDX Prostate Test to More Accurately Identify Aggressive Prostate Cancer

Apr 16, 2025

Nanostics Receives CPSA Accreditation for its Newly Relocated Clinical Laboratory at the Biotechnology Business Development Centre in Edmonton

Jun 26, 2024

Clinical study showing ClarityDX Prostate accurately predicts a patient's risk of having clinically significant prostate cancer published in Nature Digital Medicine

Apr 23, 2024

Nanostics Receives Funding from the University of Alberta Innovation Fund to Propel Adoption of the ClarityDX Prostate Test

Apr 09, 2024

Nanostics and Alberta Health Services collaborate to develop new diagnostic tools for urological diseases